IL281578A - Methods and compositions for treating aging-associated impairments using ccr3-inhibitors - Google Patents

Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Info

Publication number
IL281578A
IL281578A IL281578A IL28157821A IL281578A IL 281578 A IL281578 A IL 281578A IL 281578 A IL281578 A IL 281578A IL 28157821 A IL28157821 A IL 28157821A IL 281578 A IL281578 A IL 281578A
Authority
IL
Israel
Prior art keywords
ccr3
inhibitors
compositions
methods
treating aging
Prior art date
Application number
IL281578A
Other languages
Hebrew (he)
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of IL281578A publication Critical patent/IL281578A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL281578A 2018-09-26 2021-03-17 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors IL281578A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
IL281578A true IL281578A (en) 2021-05-31

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281578A IL281578A (en) 2018-09-26 2021-03-17 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Country Status (16)

Country Link
EP (1) EP3856195A4 (en)
JP (1) JP7528065B2 (en)
KR (1) KR20210065950A (en)
CN (1) CN112789044A (en)
AU (1) AU2019346456A1 (en)
BR (1) BR112021004938A2 (en)
CA (1) CA3111433A1 (en)
CL (1) CL2021000724A1 (en)
CO (1) CO2021003713A2 (en)
EA (1) EA202190463A1 (en)
IL (1) IL281578A (en)
MA (1) MA53743A (en)
MX (1) MX2021002967A (en)
SG (1) SG11202102105VA (en)
TW (1) TW202027752A (en)
WO (1) WO2020069008A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
PE20150925A1 (en) 2009-04-22 2015-06-14 Axikin Pharmaceuticals Inc CCR3 ANTAGONISTS OF ARYLSULFONAMIDE 2,5-DISUSTITUID
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (en) * 2010-10-07 2015-08-10 Common Crystals and Salts of CCR3 Inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN110650740A (en) * 2017-04-05 2020-01-03 万能溶剂有限公司 Methods and compositions for treating retinal-related diseases using CCR3 inhibitors
BR112019020798A2 (en) * 2017-04-05 2020-04-28 Alkahest Inc methods and compositions for treating age-related damage using ccr3 inhibitors

Also Published As

Publication number Publication date
KR20210065950A (en) 2021-06-04
CA3111433A1 (en) 2020-04-02
JP7528065B2 (en) 2024-08-05
JP2022502441A (en) 2022-01-11
MX2021002967A (en) 2021-08-11
BR112021004938A2 (en) 2021-06-01
CL2021000724A1 (en) 2021-10-15
MA53743A (en) 2022-01-05
TW202027752A (en) 2020-08-01
EA202190463A1 (en) 2021-06-29
WO2020069008A1 (en) 2020-04-02
EP3856195A1 (en) 2021-08-04
SG11202102105VA (en) 2021-04-29
EP3856195A4 (en) 2022-06-22
CN112789044A (en) 2021-05-11
AU2019346456A1 (en) 2021-04-15
CO2021003713A2 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
IL269787B (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1248153A1 (en) Methods and compositions for treating aging-associated impairments
IL277079A (en) Cartyrin compositions and methods for use
IL280134A (en) Anti-cd112r compositions and methods
EP4139348A4 (en) Methods and compositions for treating virus-associated inflammation
IL285496A (en) Methods for treating cholestasis
IL278004A (en) Methods and compositions for treating aging-associated conditions
IL275626A (en) Surface treatment compositions and methods
IL290840A (en) Compositions and methods for cd123 modification
ZA202101362B (en) Compositions and methods for treating the eye
GB201905559D0 (en) Composition and method
IL285886A (en) Compositions and methods for treating laminopathies
SG11202104448WA (en) Compositions and methods
ZA202101342B (en) Compositions and methods for treating the eye
SG11202003261PA (en) Sanitizing compositions and methods for making and using same
IL285796A (en) Methods and compositions for treating
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
GB201909542D0 (en) Composition and method
IL290325A (en) Biopharmacuetical compositions and related methods
IL277463A (en) Compositions and methods for treating pruritus
IL288440A (en) Compositions and methods for treating retinopathy
GB201817444D0 (en) Methods and compositions
ZA202101360B (en) Compositions and methods for treating the eye
ZA202101361B (en) Compositions and methods for treating the eye